ccdc40 Antibody

What is CCDC40 and why is it significant for research?

CCDC40 (coiled-coil domain containing protein 40) is a cytoplasmic protein essential for cilia and flagella motility. In humans, the canonical protein has 1142 amino acid residues with a molecular mass of 130.1 kDa, though the observed molecular weight in western blots is typically 90-100 kDa . CCDC40 is required for the assembly of the dynein regulatory complex (DRC) and inner dynein arm (IDA) complexes, which regulate ciliary beat patterns .

The protein is predominantly expressed in tissues with motile cilia, including the nasopharynx, fallopian tubes, and bronchus . CCDC40 has become a critical research target because mutations in the CCDC40 gene cause primary ciliary dyskinesia (PCD), a genetic disorder characterized by recurrent respiratory infections and abnormal left-right organ positioning (situs inversus) .

What are the common applications for CCDC40 antibodies in research?

CCDC40 antibodies are primarily used in the following applications:

For optimal results, researchers should validate each antibody in their specific experimental system, as reactivity may vary between manufacturers and applications .

How do I determine the appropriate CCDC40 antibody for my specific research application?

When selecting a CCDC40 antibody:

• Define your experimental needs: Consider the application (WB, IF, ICC), species reactivity required, and the specific epitope/region of interest.

• Review validation data: Examine published literature and manufacturer data showing the antibody's performance in applications similar to yours. For example, antibody 25049-1-AP has been validated for WB in fetal human brain tissue and A549 cells .

• Consider the antibody format: Polyclonal antibodies (like rabbit anti-CCDC40) offer high sensitivity but potentially lower specificity, while monoclonal antibodies provide higher specificity but might recognize fewer epitopes .

• Check cross-reactivity: CCDC40 has orthologs in mouse, rat, bovine, zebrafish, chimpanzee, and chicken species; confirm that your antibody recognizes your species of interest .

• Validate in your system: Always perform initial validation experiments to confirm specificity in your experimental system, including appropriate positive and negative controls.

What are the optimal protocols for using CCDC40 antibodies in immunofluorescence studies of ciliated tissues?

For optimal immunofluorescence detection of CCDC40 in ciliated tissues:

• Sample preparation:

  • For respiratory epithelial cells: Obtain samples via nasal brush biopsy and suspend in cell culture medium

  • Spread cells onto glass slides, air dry, and store at -80°C until use

• Fixation and permeabilization:

  • Treat samples with 4% paraformaldehyde to fix

  • Permeabilize with 0.2% Triton-X 100

  • Block with 1% skim milk

• Antibody incubation:

  • Primary antibody: Incubate for at least 3 hours at room temperature or overnight at 4°C

  • Secondary antibody: Incubate for 30 minutes at room temperature

  • Always include controls omitting primary antibodies

• Co-localization studies:

  • CCDC40 shows punctate cytoplasmic expression in ciliated cells

  • For axonemal localization studies, co-stain with tubulin antibodies

  • In 9+2 respiratory cells, CCDC40 localizes to the axoneme, unlike in 9+0 nodal cilia

• Imaging considerations:

  • Use high-resolution confocal microscopy for detailed subcellular localization

  • For ciliary axoneme visualization, z-stack imaging may be necessary

What challenges might I encounter when using CCDC40 antibodies in western blot analysis?

Several technical challenges may arise when performing western blot analysis with CCDC40 antibodies:

• Molecular weight discrepancy: The calculated molecular weight of CCDC40 is 130.1 kDa, but observed bands typically appear at 90-100 kDa . This discrepancy could be due to:

  • Post-translational modifications

  • Protein degradation during sample preparation

  • Detection of specific isoforms (up to 5 different isoforms have been reported)

• Sample preparation considerations:

  • CCDC40 is primarily expressed in ciliated tissues; ensure appropriate positive controls (e.g., respiratory epithelium, A549 cells)

  • Complete protein extraction may require specialized lysis buffers to solubilize membrane-associated fractions

  • Include protease inhibitors to prevent degradation

• Optimization recommendations:

  • Test a range of antibody dilutions (1:500-1:2000 for WB)

  • Optimize blocking conditions to reduce background

  • Consider longer transfer times for this high molecular weight protein

  • Validate results with multiple antibodies if possible

• Isoform detection:

  • Different antibodies may recognize different epitopes and therefore different isoforms

  • Document the exact molecular weight observed to help identify which isoform is being detected

How can I design experiments to investigate CCDC40 function in ciliary assembly and motility?

To investigate CCDC40's role in ciliary assembly and motility:

• Loss-of-function approaches:

  • siRNA or shRNA knockdown of CCDC40 in ciliated cell cultures

  • CRISPR/Cas9-mediated gene editing in cell lines or animal models

  • Analysis of naturally occurring CCDC40 mutations from PCD patients

• Functional assays:

  • High-speed videomicroscopy to analyze ciliary beat frequency and pattern

  • Transmission electron microscopy (TEM) to examine ultrastructural defects in axonemes

  • Immunofluorescence to assess localization of ciliary components like:

    • Dynein arm components (DNAH5, DNAH9, DNAI2)

    • Inner dynein arm markers (DNALI1)

    • Dynein regulatory complex proteins (GAS11)

• Model systems:

  • Human respiratory epithelial cells (primary or air-liquid interface cultures)

  • Mouse models (e.g., lnks mutant mice with truncated Ccdc40)

  • Zebrafish models for studying left-right patterning defects

  • Chlamydomonas reinhardtii for comparative evolutionary studies

• Protein interaction studies:

  • Co-immunoprecipitation to identify CCDC40 binding partners

  • Proximity labeling methods to map the CCDC40 interactome

  • Yeast two-hybrid screening to detect direct protein-protein interactions

How can CCDC40 antibodies be used to investigate primary ciliary dyskinesia (PCD) pathophysiology?

CCDC40 antibodies serve as valuable tools for investigating PCD pathophysiology through several approaches:

• Diagnostic applications:

  • Immunofluorescence analyses of patient respiratory epithelia can reveal:

    • Absent or mislocalized CCDC40 in ciliary axonemes

    • Abnormal accumulation of CCDC40 in the apical cytoplasm

    • Disrupted localization of associated proteins (DNALI1, GAS11)

• Genotype-phenotype correlation studies:

  • Compare immunostaining patterns between patients with different CCDC40 mutations

  • Current data shows that among patients with CCDC40 mutations:

    • 32% display situs solitus (normal organ arrangement)

    • 68% display situs inversus (reversed organ arrangement)

• Molecular pathology investigations:

  • CCDC40 mutations affect multiple axonemal structures:

    • Inner dynein arms (IDAs) - marked by absence of DNALI1

    • Dynein regulatory complex (DRC) - marked by absence of GAS11

    • Radial spoke defects - visible by electron microscopy

  • These structural defects translate to functional abnormalities in ciliary beating

• Therapeutic development:

  • Antibodies can be used to assess the efficacy of gene therapy or small molecule approaches

  • Monitor restoration of proper CCDC40 localization and associated protein complexes

What are the critical controls needed when using CCDC40 antibodies for studying ciliopathies?

When using CCDC40 antibodies to study ciliopathies, implement these critical controls:

How can different CCDC40 isoforms be distinguished using antibody-based techniques?

Distinguishing between the five reported CCDC40 isoforms requires strategic experimental design:

• Epitope mapping strategy:

  • Use antibodies targeting different regions of CCDC40

  • Design a panel of antibodies against:

    • N-terminal domains (common to most isoforms)

    • Specific exon junctions unique to particular splice variants

    • C-terminal domains (which may be absent in truncated isoforms)

• Western blot analysis:

  • Run high-resolution gels to separate closely migrating isoforms

  • Use gradient gels (4-12%) for optimal separation of high molecular weight proteins

  • Compare migration patterns with predicted molecular weights:

    • Canonical isoform: 130.1 kDa (calculated)

    • Observed bands may appear at 90-100 kDa or other weights depending on isoform

• RT-PCR validation:

  • Complement antibody detection with isoform-specific primers

  • Correlate protein expression with mRNA expression

  • Sequence PCR products to confirm specific isoforms

• Tissue distribution analysis:

  • Compare isoform expression across tissues with different ciliary structures

  • Document isoform-specific expression in:

    • Nasopharynx

    • Fallopian tube

    • Bronchus

    • Other ciliated tissues

What factors might contribute to inconsistent CCDC40 antibody staining in immunofluorescence experiments?

Several factors can cause variability in CCDC40 immunofluorescence staining:

• Sample preparation variables:

  • Time from sample collection to fixation

  • Fixation method and duration

  • Storage conditions of samples

  • Permeabilization efficiency

• Antibody-specific factors:

  • Lot-to-lot variability in polyclonal antibodies

  • Degradation due to improper storage

  • Optimal working dilution may vary between applications

  • Epitope accessibility in different fixation conditions

• Biological variables:

  • CCDC40 expression is cell-cycle dependent in some tissues

  • Expression varies between tissues (higher in nasopharynx, fallopian tube, bronchus)

  • Different patterns in 9+0 versus 9+2 cilia (cytoplasmic versus axonemal localization)

  • Patient mutations may affect epitope recognition

• Technical recommendations:

  • Process all experimental and control samples simultaneously

  • Standardize fixation and staining protocols

  • Include positive controls (known CCDC40-expressing tissues)

  • Validate new antibody lots before critical experiments

  • Consider multiplexed staining with ciliary markers (e.g., acetylated tubulin)

How should I interpret CCDC40 localization data in the context of ciliary dynamics?

When interpreting CCDC40 localization data:

• Normal localization patterns:

  • In wild-type respiratory cells: CCDC40 localizes to ciliary axonemes and shows punctate cytoplasmic distribution

  • In mouse nodal cells: Primarily cytoplasmic with punctate pattern and significant overlap with tubulin in apical regions

• Pathological patterns:

  • In CCDC40 mutant cells: Absence from axonemes with accumulation in apical cytoplasm

  • This pattern correlates with mislocalization of:

    • Inner dynein arm component DNALI1

    • Dynein regulatory complex protein GAS11

• Dynamic considerations:

  • CCDC40 is required for assembly of multiple axonemal complexes, suggesting early role in ciliogenesis

  • Its role may differ between:

    • Motile vs. primary cilia

    • Embryonic vs. adult tissues

    • Different ciliated cell types

• Interpretative framework:

  • Cytoplasmic localization reflects role in pre-assembly of axonemal components

  • Axonemal localization (in 9+2 cilia) suggests structural or maintenance functions

  • Co-localization studies with IDA and DRC components provide context for functional interpretation

How can I resolve discrepancies between western blot and immunofluorescence data when studying CCDC40?

Discrepancies between western blot and immunofluorescence results for CCDC40 can be addressed through:

• Technical considerations:

  • Epitope accessibility differs between techniques:

    • WB detects denatured proteins

    • IF detects proteins in their native conformation and cellular context

  • Different antibodies may recognize different epitopes with varying accessibility in each technique

• Resolution strategies:

  • Use multiple antibodies targeting different CCDC40 epitopes

  • Perform peptide competition assays to confirm specificity

  • Validate with genetic approaches (siRNA knockdown, CRISPR/Cas9)

  • Include known positive and negative controls

• Interpretation framework:

  • WB band at 90-100 kDa instead of calculated 130.1 kDa may indicate:

    • Post-translational modifications

    • Proteolytic processing

    • Detection of specific isoforms

  • IF cytoplasmic staining without axonemal staining in some cell types is consistent with CCDC40's role in pre-assembly of axonemal components

• Complementary approaches:

  • Correlate with mRNA expression (RT-PCR)

  • Use mass spectrometry to identify protein species

  • Perform subcellular fractionation to confirm localization

How might CCDC40 antibodies be utilized in high-throughput screening for ciliopathy therapeutics?

CCDC40 antibodies could enable several high-throughput screening approaches for ciliopathy therapeutics:

• Cell-based phenotypic screens:

  • Generate reporter cell lines expressing CCDC40-fluorescent protein fusions

  • Develop high-content imaging assays to monitor:

    • CCDC40 localization (cytoplasmic vs. axonemal)

    • Co-localization with partner proteins (DNALI1, GAS11)

    • Ciliary beat patterns and frequencies

• Restoration assays in patient-derived cells:

  • Screen compounds for ability to rescue:

    • CCDC40 localization in cells with missense mutations

    • Assembly of IDA and DRC components

    • Functional ciliary beating

• Automated immunofluorescence platforms:

  • Develop multiplexed antibody panels to simultaneously assess:

    • CCDC40 expression and localization

    • Ciliary structure markers

    • Functional readouts of ciliary activity

• Translational applications:

  • Patient stratification based on CCDC40 mutation type and protein expression pattern

  • Biomarker development for monitoring therapeutic efficacy

  • Target engagement studies for small molecules affecting CCDC40 function

What novel approaches could be developed to study CCDC40 interactions with other ciliary proteins?

Innovative approaches to study CCDC40 protein interactions include:

• Proximity-dependent labeling techniques:

  • BioID or TurboID fusion proteins to identify proteins in close proximity to CCDC40

  • APEX2 labeling for electron microscopy visualization of interaction domains

  • Split-BioID for detecting specific protein-protein interactions in living cells

• Live-cell imaging approaches:

  • FRET/FLIM to detect direct interactions between CCDC40 and partner proteins

  • Optogenetic tools to manipulate CCDC40 interactions temporally

  • Super-resolution microscopy (STORM, PALM) to visualize nanoscale organization within cilia

• Structural biology integration:

  • Cryo-electron tomography of cilia from wild-type and CCDC40-mutant cells

  • Correlative light and electron microscopy with CCDC40 antibodies

  • In-cell NMR to study CCDC40 structural dynamics

• Systems biology approaches:

  • Integrate protein interaction data with:

    • Transcriptomic profiles

    • Proteomic datasets

    • Genetic interaction networks

  • Computational modeling of ciliary assembly with CCDC40 as a key component

How will advances in antibody technology impact future CCDC40 research?

Emerging antibody technologies will transform CCDC40 research:

• Single-domain antibodies and nanobodies:

  • Smaller size enables better penetration into ciliary compartments

  • Potential for live-cell imaging of CCDC40 dynamics

  • May recognize epitopes inaccessible to conventional antibodies

• Recombinant antibody fragments:

  • More consistent performance than polyclonal antibodies

  • Can be engineered for specific applications

  • Potential for intrabody expression to manipulate CCDC40 function in living cells

• Spatiotemporal antibody applications:

  • PhotoActivatable antibodies for controlled binding

  • Antibody-drug conjugates for targeted ciliary manipulations

  • Bi-specific antibodies to study CCDC40 co-localization with partners

• Integration with emerging technologies:

  • Antibody-based proximity proteomics

  • Mass cytometry (CyTOF) for single-cell analysis of CCDC40 in heterogeneous tissues

  • Spatial transcriptomics correlated with antibody-based protein localization